Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On April 1, 2017, the Compensation Committee of the Board of Directors (the “Committee”) of Accelerate Diagnostics, Inc. (the “Company”) approved and the Company entered into a First Amendment to the Restricted Stock Unit Agreement For Joan Martin Under the Accelerate Diagnostics, Inc. 2012 Omnibus Equity Incentive Plan (the “Amendment”). The original Restricted Stock Unit Agreement awarded Mr. Martin, Executive Vice President & Head of Europe, Middle East, and Africa, 40,250 restricted stock units (“RSUs”) on April 1, 2016 to the Company’s 2012 Omnibus Equity Incentive Plan. The RSUs were scheduled to vest 40% on March 19, 2017 and the remaining 60% in 36 equal monthly installments thereafter. The Amendment modified the vesting schedule for the RSUs awarded to Mr. Martin to vest 40% on March 19, 2017 and the remaining 60% in three equal annual installments thereafter.

About Accelerate Diagnostics, Inc. (NASDAQ:AXDX)

Accelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions that improve patient outcomes and lower healthcare costs through the diagnosis of serious infections. The Company’s technology platform is built to address these challenges by delivering testing of infectious pathogens in various patient sample types. The Company is focused on the development of a rapid diagnostic platform, the Accelerate ID/AST System (ID/AST System or Accelerate ID/AST System), intended for the diagnosis of infectious pathogens. The ID/AST System utilizes genotypic technology to identify (ID) infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. The ID/AST System features walk-away automation and consists of a fixed instrument and single-use test kit.

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Recent Trading Information

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) closed its last trading session up +0.25 at 25.15 with 246,132 shares trading hands.